*By Bridgette Webb*
Drugmaker Merck announced earlier this month it will slash prices on several drugs by 10 percent or more.
But there is a catch: the price rollback will only affect some of the smaller products in its portfolioーlike Hepatitis C drug, Zepatier, which accounts for about 4 percent of the company's salesーand not top sellers like cancer treatment Keytruda.
"Their scope is relatively limited," said Peter Loftus, a Reporter for the Wall Street Journal, during an interview on Cheddar Monday. "If you think about the total sales that Merck generatesーit's a relatively small percentage."
Merck's announcement was met with praise from the Trump administration. Health and Human Services Secretary Alex Azar claimed the drop in prices was spurred by Trump's latest crackdown on pharmaceutical companies.
Other big pharma names are following suit: Pfizer and Novartis announced they will freeze price increases for the rest of the year, earning them congratulatory tweets from the president.
Despite all of the price freezes and drops, Loftus says that patients may not actually see any real savings.
"I don't think you can say on a widespread basis, and really for the average drug or patient, that prices are coming down, there are still price increases."
For the full segment, [click here.]
(https://cheddar.com/videos/drugmakers-tout-lower-prices)
It’s been a month since a Maryland man became the second person to receive a transplanted heart from a pig –- and hospital video released Friday shows he’s working hard to recover.
CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers.
October is Breast Awareness Cancer Month as the disease affects millions of American families. Elissa Kalver, founder of Wegotthis.org, joined Cheddar News to explain how breast cancer inspired her to create her own nonprofit and provided some details of her personal battle while maintaining a family.
With warmer oceans serving as fuel, Atlantic hurricanes are now more than twice as likely as before to rapidly intensify from wimpy minor hurricanes to powerful and catastrophic, a study said Thursday.
